Literature DB >> 18091190

The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.

Georges Gharabawi1, Cynthia Bossie, Ibrahim Turkoz, Mary Kujawa, Ramy Mahmoud, George Simpson.   

Abstract

This post hoc analysis explored the role of insight as a mediator of functioning in a 52-week, double-blind, international trial of 323 patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. Measures included the Positive and Negative Syndrome Scale (PANSS) insight item, PANSS factors, Clinical Global Impressions-Severity (CGI-S), Strauss-Carpenter Levels of Functioning (LOF), Personal and Social Performance (PSP) scale, and a cognitive test battery. Correlation/regression analyses examined associations between demographic and clinical characteristics, including insight, and functional measures. Insight scores correlated significantly with CGI-S, PANSS subscales, PSP, LOF, and several cognitive measures. Regression models demonstrated that changes in insight, changes in negative symptoms, and study duration were significantly associated with PSP and LOF total change scores. Findings identified important variables to consider for intervention to improve functioning in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18091190     DOI: 10.1097/NMD.0b013e31815c1982

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  9 in total

Review 1.  Brexpiprazole: so far so good.

Authors:  Saibal Das; Preeti Barnwal; Blessed Winston A; Somnath Mondal; Indranil Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

2.  Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features.

Authors:  Hanan D Trotman; Brian Kirkpatrick; Michael T Compton
Journal:  Schizophr Res       Date:  2011-03       Impact factor: 4.939

Review 3.  Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia.

Authors:  Irene Bighelli; Alessandro Rodolico; Spyridon Siafis; Myrto T Samara; Wulf-Peter Hansen; Salvatore Salomone; Eugenio Aguglia; Pierfelice Cutrufelli; Ingrid Bauer; Lio Baeckers; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30

4.  Intrinsic motivation as a mediator of relationships between symptoms and functioning among individuals with schizophrenia spectrum disorders in a diverse urban community.

Authors:  Ann-Marie Yamada; Karen K Lee; Tam Q Dinh; Concepción Barrio; John S Brekke
Journal:  J Nerv Ment Dis       Date:  2010-01       Impact factor: 2.254

5.  Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder.

Authors:  Julia Ermel; Cameron S Carter; James M Gold; Angus W MacDonald; J Daniel Ragland; Steven M Silverstein; Milton E Strauss; Deanna M Barch
Journal:  Schizophr Res Cogn       Date:  2017-05-09

6.  Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials.

Authors:  Mingjun Zhao; Bin Qin; Yage Mao; Hailing Wang; Aiqin Wang; Chuansheng Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-11       Impact factor: 2.989

7.  Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial.

Authors:  Paul H Lysaker; Peter J Weiden; Xiaowu Sun; Amy K O'Sullivan; Joseph P McEvoy
Journal:  BMC Psychiatry       Date:  2022-08-28       Impact factor: 4.144

8.  Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia.

Authors:  Ibrahim Turkoz; Cynthia A Bossie; Bryan Dirks; Carla M Canuso
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

9.  Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics.

Authors:  Nan Li; Yu Feng; Huafei Lu; Shang Li Cai; Jianmin Zhuo; Tianmei Si; Lili Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-03-22       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.